Geron Corporation Posts Mixed Results; Receives First Milestone Payment (GERN)

Geron Corporation

reports Q3 earnings loss of $0.19 versus consensus of $0.20 loss. Geron Corporation reports revenues of $546,000 versus consensus of $930,000. In Q3, GE Healthcare

launched the first human cellular assay product, human cardiomyocytes or heart muscle cells, for testing potential cardiac toxicity of candidate drug compounds in development. The first commercial sale of this product occurred in October 2010, triggering a milestone payment to Geron. The first patient was enrolled in the Phase 1 clinical trial of hESC-derived oligodendrocyte progenitor cells, GRNOPC1. The primary objective of this Phase 1 study is to assess the safety and tolerability of GRNOPC1 in patients with "complete" American Spinal Injury Association (

) Impairment Scale grade A thoracic spinal cord injuries. Shares of GERN are bid higher in the after-hours.